Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...

Relapses in a common ... of cancer cell re-wiring. Abd technology will allow development of a new generation of drugs to hard-to-drug and intrinsically disordered proteins." AML with a FLT3 ...

The AACR poster presentation will provide an update on the data in AML patients most recently presented at the American Society of Hematology (ASH) Annual Meeting 2024 showing that ICT01 administered ...

At the moment, less than 30% of AML patients live beyond five years, despite a 60% to 80% remission rate with current first-line therapies. The intravenous formulation of azacitidine – sold by ...